To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Femprox Effective In Treating Sexual Arousal Disorder In Women URL: http://www.pslgroup.com/dg/14D466.htm Doctor's Guide December 2, 1999
ROBBINSVILLE, N.J. -- December 2, 1999 -- NexMed, Inc. announced that its Femprox cream, incorporating alprostadil (prostaglandin E1), for treating female sexual arousal disorder (FSAD) demonstrated a positive effect on increasing blood flow to the clitoris and labia in 18 female subjects. Dr. Edgardo F. Becher, the principal investigator for the study and President of the Latin American Society for Impotence Research, conducted the study with 18 women between 18 and 61 years old. Using duplex ultrasonography, the study measured blood flow through the major arterial blood vessels in the clitoris. In addition to labial and clitoral engorgement, 13 subjects reported a " pleasant" warm sensation. No systemic side effects were evidenced and local side effects were minimal. Approximately 47 million American women, including 75 percent post-menopausal and 25 percent pre-menopausal women, are estimated to suffer from FSAD with symptoms that include the inability to experience sexual arousal or orgasm. The causes of FSAD are complicated and may include, in some cases, psychological problems such as depression, stress and fatigue. Many patients experience physical discomfort due to inadequate natural lubrication that may be a result of inadequate blood flow in the genital area, which is often associated with menopause, diabetes and hysterectomies. Women suffering from FASD may have poor or inadequate blood flow to the genital area resulting in inadequate lubricating secretions for sexual intercourse. These women do not have adequate lubricating secretions and do not become sexually aroused with normal sexual stimulation. The Femprox cream is a promising treatment under development designed to improve the blood flow to the genital area of females and restore the natural ability of the genital tissues to engorge with blood and produce lubricating secretions during sexual stimulation, thus improving sexual arousal and pleasure. Dr. James L. Yeager, Vice-President for Research and Development, commented, "Topical treatments for male and female impotence are of increasing interest because they may offer advantages over currently marketed treatments. The results of this blood flow study are very encouraging and demonstrate a potentially new therapeutic approach to treat FSAD." Dr. Edgardo F. Becher presented his findings at the recent Boston University School of Medicine's New Perspective in the Management of Female Sexual Dysfunction. He commented, "The results indicate that the Femprox cream may also have applications in diagnosing circulatory problems as a cause of FSAD." The Femprox cream incorporates alprostadil (prostaglandin E1), an off-patent vasodilator drug recognized for treating male erectile dysfunction (ED), commonly known as impotence, and NexMed's proprietary NexACT transdermal drug delivery system. The company is also developing Alprox-TD cream, its proprietary topical formulation for treating ED. In an August 1999 press release which announced U.S. Phase I clinical trial results, the Femprox cream showed statistically significant (p<.05), dose-related improvements in arousal, lubrication, engorgement, pleasure, and relaxation. The product is intended to improve vaginal secretions and thereby increase sexual arousal and pleasure during intercourse. In vitro and in vivo studies indicate that the NexACT transdermal drug delivery system promotes the rapid delivery of alprostadil through the outer barrier of the skin as well as below the skin. U.S. Phase II clinical trials are expected to begin soon. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.